334 related articles for article (PubMed ID: 23226581)
1. Structure, regulation, signaling, and targeting of abl kinases in cancer.
Hantschel O
Genes Cancer; 2012 May; 3(5-6):436-46. PubMed ID: 23226581
[TBL] [Abstract][Full Text] [Related]
2. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Hantschel O; Grebien F; Superti-Furga G
Cancer Res; 2012 Oct; 72(19):4890-5. PubMed ID: 23002203
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
5. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
6. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T; Ashihara E; Kimura S
Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
[TBL] [Abstract][Full Text] [Related]
7. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Nimmanapalli R; Bhalla K
Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
[TBL] [Abstract][Full Text] [Related]
9. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Gumireddy K; Baker SJ; Cosenza SC; John P; Kang AD; Robell KA; Reddy MV; Reddy EP
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1992-7. PubMed ID: 15677719
[TBL] [Abstract][Full Text] [Related]
10. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
12. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Mian AA; Metodieva A; Badura S; Khateb M; Ruimi N; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
BMC Cancer; 2012 Sep; 12():411. PubMed ID: 22985168
[TBL] [Abstract][Full Text] [Related]
13. New insights into small-molecule inhibitors of Bcr-Abl.
Schenone S; Bruno O; Radi M; Botta M
Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
[TBL] [Abstract][Full Text] [Related]
14. New strategies in controlling drug resistance.
Frame D
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
[TBL] [Abstract][Full Text] [Related]
15. Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.
Hossain S; Dubielecka PM; Sikorski AF; Birge RB; Kotula L
Genes Cancer; 2012 May; 3(5-6):402-13. PubMed ID: 23226578
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Kakarala KK; Jamil K
J Biomol Struct Dyn; 2022 Sep; 40(15):6889-6909. PubMed ID: 33682622
[TBL] [Abstract][Full Text] [Related]
17. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
18. Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".
Jahnke W; Paladini J; Habazettl JM; Wiget A; Loo A; Cowan Jacob SW; Grzesiek S; Manley PW
Angew Chem Int Ed Engl; 2022 Nov; 61(46):e202117276. PubMed ID: 36257909
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
20. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
